Sepracor now part of Dainippon Sumitomo
This article was originally published in Scrip
Dainippon Sumitomo Pharma (DSP) has now completed its roughly $2.6 billion acquisition of Sepracor, following a second tender offer ending on October 19th in which it raised its holding in the US firm to around 87%.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.